Please assess the completion status of the following clinical trial:

Trial Title: Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) Class 1 or 2 or 3~* Scheduled to undergo an elective abdominal surgical procedure under general anesthesia; and:~  * expected to undergo neuromuscular relaxation with rocuronium for~endotracheal intubation; and~* expected to require at least one maintenance dose of rocuronium; and~* expected to require active reversal of neuromuscular blockade; and~* expected to require clinical or subjective neuromuscular monitoring only; and~* expected to recover in the PACU~  * Arm that is accessible for measuring the TOF ratio in the PACU~ * Sexually active female patient of child-bearing potential must agree to use a~medically accepted method of contraception through seven days after receiving~protocol-specified medication.~Exclusion Criteria:~* Anatomical malformations that may lead to difficult intubation~* Neuromuscular disorder(s) that may affect neuromuscular blockade and/or trial assessments~* Dialysis-dependent or has or is suspected of having severe renal insufficiency~* Significant hepatic dysfunction~* Family history of malignant hyperthermia~* Cardiac pacemaker~* Allergy to study treatments or its/their excipients, to opioids / opiates, sugammadex, muscle relaxants or their excipients, or other medication(s) used during general anesthesia~* Toremifene before or within 24 hours of study drug administration~* Scheduled for an overnight stay (or \>12 hours) in PACU~* Expected transfer to an Intensive Care Unit after surgery~* Pregnant, intention to become pregnant between randomization and the Day 30 pregnancy follow-up visit~* Breast-feeding.~* Investigational drug(s) within 30 days of randomization on this study~* Participation in any other clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial~* Participant or family member is among the personnel of the investigational or Sponsor staff directly involved with this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): Participants receive sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery
- Neostigmine/glycopyrrolate (Type: ACTIVE_COMPARATOR): Participants receive neostigmine/glycopyrrolate per usual practice

Based on this trial design, predict the completion outcome and termination type (if applicable).